ACOG: רווח נקי למניה (EPS TTM) alphacognition.com

The high scalability of Alpha Cognition (ACOG) is driven by patents for Alzheimer's therapy, which is confirmed by the EPS trend over the last 12 months shown on GURU.Markets; this chart currently stands at -1.11. Alpha Cognition (ACOG) is developing partnerships with neurocenters to improve cognitive functions. Simultaneously, management is establishing distribution networks following the approval of its primary drug, earning the trust of investors.

Utilizing external contract manufacturing capacities for compound production reduces capital expenditures for Alpha Cognition (ACOG), directly impacting the bottom line. By analyzing the current trailing 12-month EPS, an investor assesses the net income allocated per share, which enables the determination of real operational efficiency and the fundamental value of the business relative to its market capitalization.